CPHI Milan 2026 from October 6 to 8
Promoting Songdo Campus Manufacturing Capabilities
Business Meetings with Potential Clients

Lotte Biologics will participate in major bio conferences in Europe, Japan, and the United States in October, aiming to showcase its global Contract Development and Manufacturing Organization (CDMO) competitiveness.

Lotte Biologics' exclusive exhibition booth at CPHI Milan 2026. Lotte Biologics

Lotte Biologics' exclusive exhibition booth at CPHI Milan 2026. Lotte Biologics

View original image

On September 14, Lotte Biologics announced that it will be present at the world pharmaceutical exhibition "CPHI Milan 2026," scheduled to take place in Milan, Italy from October 6 to 8, and at "Bio Japan 2026," which will be held in Yokohama, Japan from October 7 to 9. In addition, the company will attend "World ADC San Diego" in San Diego, United States from October 12 to 15.


CPHI Milan, the world's largest pharmaceutical and biopharma exhibition, is held in major European cities each year. At this event, Lotte Biologics plans to highlight the large-scale commercial manufacturing capabilities of its Songdo Bio Campus, which is approaching GMP readiness, as well as the "dual site" competitiveness that leverages production bases in both Korea and the United States.


On the first and second days of the event, the company will hold "In-booth Presentations" to showcase its large-scale commercial manufacturing capacity and strengths in the bispecific antibody sector. It will also expand business meetings with potential client companies by utilizing private meeting rooms of various sizes.


At Bio Japan 2026, Lotte Biologics will set up an exclusive exhibition booth to present technologies such as its automated Manufacturing Control System (MCS), digital twin, and Computational Fluid Dynamics (CFD) simulations, which are designed to enhance production efficiency and quality stability. The company will also conduct partnering meetings with global potential clients.



At World ADC San Diego, a specialist event focusing on the ADC field, Lotte Biologics will spotlight its antibody-drug conjugate (ADC) production capabilities. The company intends to introduce the strengths of its own ADC platform through a presentation session and emphasize its technological competitiveness in the global ADC CDMO business.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing